Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Position Boosted by Financial Perspectives Inc

Posted by William Tyler on Apr 23rd, 2024

Financial Perspectives Inc raised its holdings in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Free Report) by 80.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,750 shares of the company’s stock after acquiring an additional 3,000 shares during the quarter. Financial Perspectives Inc’s holdings in Werewolf Therapeutics were worth $26,000 at the end of the most recent quarter.

Analyst Upgrades and Downgrades

Separately, JMP Securities assumed coverage on Werewolf Therapeutics in a report on Wednesday, April 3rd. They issued a “mkt outperform” rating and a $12.00 target price for the company.

Read Our Latest Report on HOWL

Werewolf Therapeutics Price Performance

Shares of HOWL traded up $0.35 on Tuesday, reaching $6.44. 393,885 shares of the stock traded hands, compared to its average volume of 246,488. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14. Werewolf Therapeutics, Inc. has a 12 month low of $1.57 and a 12 month high of $8.19. The stock’s 50-day moving average price is $6.26 and its 200-day moving average price is $4.42.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative return on equity of 32.25% and a negative net margin of 187.37%. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.75 million. On average, research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Werewolf Therapeutics Profile

(Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.